Standard stepwise therapy for overactive bladder (OAB) begins with conservative therapies such as lifestyle interventions and behavioral approaches. Medications—anticholinergics or beta-3 agonists—are ...

While potty training is probably a distant childhood memory, the panicked feeling of “I need to pee right now and I don’t know if I can make it to the bathroom in time” is something many adults still ...

With overactive bladder (OAB), a person may need to use the bathroom often or experience urine leakage. Yet various treatments can help manage the condition. Share on Pinterest Terry Vine/Getty Images ...

Overactive Bladder (OAB) is more than the occasional bathroom break. When your bladder is working overtime and nothing has ...

Please provide your email address to receive an email when new articles are posted on . Results from the EMPOWUR extension study presented at the virtual International Continence Society Annual ...

Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The novel muscarinic M3 receptor ...

Jan. 25, 2013 -- The FDA has approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women 18 and older. The condition affects more than 20 million American women, ...

New York, USA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Global Overactive Bladder Treatment Market to Exhibit Substantial Growth at a CAGR of ~4% by 2032 | DelveInsight The overactive bladder treatment ...

To make life easier for people with a common bladder condition, Medtronic is digging in far away from urinary tract.

NEW YORK, Aug. 3, 2017 /PRNewswire/ -- "Global overactive bladder treatment market is projected to grow at a CAGR of 2.9%." The global overactive bladder treatment market is estimated to grow at a ...